Pfizer vaccine 5-11 years, data submitted to Fda

Pfizer and BioNTech announce that they have submitted data from the phase 2/3 study on the Covid vaccine in children aged 5 to 11 to the US regulatory body FDA. “In the coming weeks”, the two companies announce, will follow the submission of the application for the emergency use authorization (Eua) of the vaccine in this population. The data, Pfizer and BioNTech continue, “will also be transmitted” to the European agency “Ema and other regulatory authorities”.